NASDAQ:DRRX

DURECT Competitors

$1.47
+0.02 (+1.38 %)
(As of 07/23/2021 02:27 PM ET)
Add
Compare
Today's Range
$1.40
$1.48
50-Day Range
$1.32
$1.82
52-Week Range
$1.28
$2.95
Volume26,426 shs
Average Volume656,271 shs
Market Capitalization$334.29 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41

DURECT (NASDAQ:DRRX) Vs. HRTX, AMTI, ZEAL, ARQT, RPTX, and KURA

Should you be buying DRRX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to DURECT, including Heron Therapeutics (HRTX), Applied Molecular Transport (AMTI), Zealand Pharma A/S (ZEAL), Arcutis Biotherapeutics (ARQT), Repare Therapeutics (RPTX), and Kura Oncology (KURA).

DURECT (NASDAQ:DRRX) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, dividends, profitability, earnings, institutional ownership and valuation.

Risk & Volatility

DURECT has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.38, indicating that its share price is 38% more volatile than the S&P 500.

Profitability

This table compares DURECT and Heron Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DURECT-2.33%-28.91%-16.67%
Heron Therapeutics-274.23%-88.33%-61.41%

Institutional & Insider Ownership

52.2% of DURECT shares are held by institutional investors. Comparatively, 88.9% of Heron Therapeutics shares are held by institutional investors. 5.2% of DURECT shares are held by company insiders. Comparatively, 4.6% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for DURECT and Heron Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DURECT00503.00
Heron Therapeutics00303.00

DURECT currently has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Heron Therapeutics has a consensus target price of $28.6667, suggesting a potential upside of 120.34%. Given DURECT's higher probable upside, analysts clearly believe DURECT is more favorable than Heron Therapeutics.

Valuation and Earnings

This table compares DURECT and Heron Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00
Heron Therapeutics$88.64 million15.07$-227,280,000.00($2.50)-5.25

DURECT has higher earnings, but lower revenue than Heron Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Heron Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

DURECT beats Heron Therapeutics on 9 of the 13 factors compared between the two stocks.

DURECT (NASDAQ:DRRX) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Valuation & Earnings

This table compares DURECT and Applied Molecular Transport's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00
Applied Molecular TransportN/AN/A$-66,560,000.00($2.91)-11.74

DURECT has higher revenue and earnings than Applied Molecular Transport. DURECT is trading at a lower price-to-earnings ratio than Applied Molecular Transport, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

52.2% of DURECT shares are owned by institutional investors. Comparatively, 63.4% of Applied Molecular Transport shares are owned by institutional investors. 5.2% of DURECT shares are owned by insiders. Comparatively, 26.7% of Applied Molecular Transport shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares DURECT and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DURECT-2.33%-28.91%-16.67%
Applied Molecular TransportN/A-51.27%-48.04%

Analyst Recommendations

This is a summary of current ratings and recommmendations for DURECT and Applied Molecular Transport, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DURECT00503.00
Applied Molecular Transport00203.00

DURECT presently has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Applied Molecular Transport has a consensus target price of $80.3333, suggesting a potential upside of 135.10%. Given DURECT's higher probable upside, equities analysts clearly believe DURECT is more favorable than Applied Molecular Transport.

Summary

DURECT beats Applied Molecular Transport on 7 of the 11 factors compared between the two stocks.

Zealand Pharma A/S (NASDAQ:ZEAL) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.

Profitability

This table compares Zealand Pharma A/S and DURECT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zealand Pharma A/S-243.60%-59.47%-45.20%
DURECT-2.33%-28.91%-16.67%

Valuation & Earnings

This table compares Zealand Pharma A/S and DURECT's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zealand Pharma A/S$54.13 million23.84$-129,720,000.00($3.38)-8.77
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00

DURECT has lower revenue, but higher earnings than Zealand Pharma A/S. DURECT is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

3.5% of Zealand Pharma A/S shares are held by institutional investors. Comparatively, 52.2% of DURECT shares are held by institutional investors. 5.2% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zealand Pharma A/S and DURECT, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zealand Pharma A/S00203.00
DURECT00503.00

Zealand Pharma A/S currently has a consensus target price of $43.00, indicating a potential upside of 45.07%. DURECT has a consensus target price of $7.00, indicating a potential upside of 382.76%. Given DURECT's higher possible upside, analysts clearly believe DURECT is more favorable than Zealand Pharma A/S.

Volatility & Risk

Zealand Pharma A/S has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500.

Summary

DURECT beats Zealand Pharma A/S on 10 of the 13 factors compared between the two stocks.

DURECT (NASDAQ:DRRX) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

52.2% of DURECT shares are owned by institutional investors. Comparatively, 93.1% of Arcutis Biotherapeutics shares are owned by institutional investors. 5.2% of DURECT shares are owned by company insiders. Comparatively, 39.0% of Arcutis Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for DURECT and Arcutis Biotherapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DURECT00503.00
Arcutis Biotherapeutics00603.00

DURECT currently has a consensus price target of $7.00, suggesting a potential upside of 382.76%. Arcutis Biotherapeutics has a consensus price target of $54.40, suggesting a potential upside of 119.53%. Given DURECT's higher probable upside, research analysts plainly believe DURECT is more favorable than Arcutis Biotherapeutics.

Profitability

This table compares DURECT and Arcutis Biotherapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DURECT-2.33%-28.91%-16.67%
Arcutis BiotherapeuticsN/A-52.09%-47.92%

Valuation and Earnings

This table compares DURECT and Arcutis Biotherapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00
Arcutis BiotherapeuticsN/AN/A$-135,680,000.00($3.80)-6.50

DURECT has higher revenue and earnings than Arcutis Biotherapeutics. DURECT is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

DURECT has a beta of 1.41, indicating that its share price is 41% more volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Summary

DURECT beats Arcutis Biotherapeutics on 7 of the 12 factors compared between the two stocks.

Repare Therapeutics (NASDAQ:RPTX) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, dividends and valuation.

Earnings and Valuation

This table compares Repare Therapeutics and DURECT's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repare Therapeutics$140,000.008,829.79$-53,420,000.00($2.66)-12.56
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00

DURECT has higher revenue and earnings than Repare Therapeutics. DURECT is trading at a lower price-to-earnings ratio than Repare Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

70.3% of Repare Therapeutics shares are held by institutional investors. Comparatively, 52.2% of DURECT shares are held by institutional investors. 33.6% of Repare Therapeutics shares are held by insiders. Comparatively, 5.2% of DURECT shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Repare Therapeutics and DURECT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repare TherapeuticsN/A-21.30%-17.19%
DURECT-2.33%-28.91%-16.67%

Analyst Recommendations

This is a summary of current ratings for Repare Therapeutics and DURECT, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repare Therapeutics00413.20
DURECT00503.00

Repare Therapeutics presently has a consensus target price of $45.00, suggesting a potential upside of 35.62%. DURECT has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Given DURECT's higher probable upside, analysts plainly believe DURECT is more favorable than Repare Therapeutics.

Summary

Repare Therapeutics beats DURECT on 8 of the 14 factors compared between the two stocks.

Kura Oncology (NASDAQ:KURA) and DURECT (NASDAQ:DRRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

Kura Oncology has a beta of 1.9, suggesting that its stock price is 90% more volatile than the S&P 500. Comparatively, DURECT has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Kura Oncology and DURECT, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kura Oncology01802.89
DURECT00503.00

Kura Oncology presently has a consensus target price of $42.5556, suggesting a potential upside of 128.42%. DURECT has a consensus target price of $7.00, suggesting a potential upside of 382.76%. Given DURECT's stronger consensus rating and higher possible upside, analysts clearly believe DURECT is more favorable than Kura Oncology.

Earnings & Valuation

This table compares Kura Oncology and DURECT's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kura OncologyN/AN/A$-89,630,000.00($1.69)-11.02
DURECT$30.11 million11.10$-580,000.00($0.07)-21.00

DURECT has higher revenue and earnings than Kura Oncology. DURECT is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kura Oncology and DURECT's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kura OncologyN/A-22.15%-20.63%
DURECT-2.33%-28.91%-16.67%

Insider and Institutional Ownership

52.2% of DURECT shares are owned by institutional investors. 4.9% of Kura Oncology shares are owned by insiders. Comparatively, 5.2% of DURECT shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

DURECT beats Kura Oncology on 8 of the 13 factors compared between the two stocks.


DURECT Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$13.12+0.6%$1.34 billion$88.64 million-5.23
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
1.7$34.17+2.3%$1.31 billionN/A-13.40Insider Selling
Short Interest Increase
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.3$29.64+1.5%$1.29 billion$54.13 million-8.17
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.7$24.71+1.0%$1.24 billionN/A-7.06Analyst Downgrade
Gap Down
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.7$33.41+0.4%$1.24 billion$140,000.00-8.77
Kura Oncology logo
KURA
Kura Oncology
1.2$18.62+0.3%$1.23 billionN/A-10.76
FibroGen logo
FGEN
FibroGen
1.6$13.34+2.2%$1.23 billion$176.32 million-6.60Analyst Downgrade
Kronos Bio logo
KRON
Kronos Bio
1.9$21.87+0.3%$1.23 billionN/A-5.83News Coverage
uniQure logo
QURE
uniQure
1.8$26.35+0.5%$1.21 billion$37.51 million-8.53Upcoming Earnings
Analyst Downgrade
Unusual Options Activity
JANX
Janux Therapeutics
1.3$30.37+0.0%$1.21 billionN/A0.00Quiet Period Expiration
Generation Bio logo
GBIO
Generation Bio
1.9$20.84+0.7%$1.18 billionN/A-7.06
Endo International logo
ENDP
Endo International
1.7$4.93+0.8%$1.15 billion$2.90 billion12.33Unusual Options Activity
News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$30.97+0.5%$1.14 billionN/A-18.43Analyst Upgrade
News Coverage
Precigen logo
PGEN
Precigen
1.7$5.44+2.2%$1.12 billion$103.18 million-7.16
ImmunoGen logo
IMGN
ImmunoGen
1.5$5.60+0.0%$1.12 billion$132.30 million-20.00Upcoming Earnings
MannKind logo
MNKD
MannKind
1.4$4.46+0.4%$1.11 billion$65.14 million-17.15Analyst Upgrade
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.5$9.56+1.6%$1.10 billion$46.55 million-11.80
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$19.70+1.5%$1.09 billion$248.17 million34.56Upcoming Earnings
News Coverage
Olema Pharmaceuticals logo
OLMA
Olema Pharmaceuticals
1.8$26.03+4.3%$1.05 billionN/A-7.61Insider Selling
Short Interest Increase
News Coverage
NRXP
NRx Pharmaceuticals
1.0$21.70+24.2%$1.04 billionN/A0.00News Coverage
Gap Up
Nkarta logo
NKTX
Nkarta
1.7$31.53+2.4%$1.03 billion$120,000.00-1.00Analyst Downgrade
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$32.73+0.2%$1.03 billionN/A-7.79Short Interest Increase
ChemoCentryx logo
CCXI
ChemoCentryx
1.9$14.52+3.2%$1.01 billion$64.89 million-15.78Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.5$20.07+3.4%$1.01 billionN/A-14.65Analyst Upgrade
ESSA Pharma logo
EPIX
ESSA Pharma
1.7$24.89+1.2%$1.01 billionN/A-25.66News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.7$19.59+2.4%$1.00 billionN/A-4.74
Zogenix logo
ZGNX
Zogenix
1.7$17.94+3.9%$1.00 billion$13.64 million-4.17Analyst Revision
DSGN
Design Therapeutics
1.3$17.95+1.7%$998.38 millionN/A0.00Gap Up
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.3$20.79+1.8%$990.23 million$349.85 million415.80Analyst Report
Insider Selling
EWTX
Edgewise Therapeutics
1.7$20.10+2.0%$989.93 millionN/A0.00
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$24.39+1.2%$987.80 million$800.40 million23.01
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.1$14.36+1.5%$979.78 millionN/A-5.09News Coverage
Gap Up
Humanigen logo
HGEN
Humanigen
2.4$16.40+3.6%$968.91 million$310,000.00-4.84News Coverage
Kinnate Biopharma logo
KNTE
Kinnate Biopharma
1.9$21.96+2.1%$955.26 millionN/A-4.16Analyst Upgrade
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$12.48+2.9%$952.10 million$17.40 million-5.43News Coverage
Positive News
Gap Up
Shattuck Labs logo
STTK
Shattuck Labs
1.5$22.32+3.0%$935.21 million$9.93 million-9.46Short Interest Increase
Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$25.38+1.7%$910.89 million$41.82 million-8.35
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.7$13.63+1.0%$889.77 million$71.86 million-3.16
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
2.0$24.95+1.0%$879.49 million$310.02 million21.51
Omeros logo
OMER
Omeros
1.6$14.10+1.0%$878.85 million$73.81 million-5.78
GHRS
GH Research
1.7$17.33+3.9%$875.51 millionN/A0.00Analyst Report
Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$36.87+2.8%$859.07 million$10 million-15.43Analyst Downgrade
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$35.22+0.9%$848.10 million$10.39 million-12.81Analyst Downgrade
Gap Up
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$41.80+1.9%$843.94 million$122.47 million-11.39
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$12.06+1.4%$838.89 million$830,000.00-7.63Analyst Upgrade
Insider Selling
Prometheus Biosciences logo
RXDX
Prometheus Biosciences
1.6$21.40+4.6%$831.82 million$1.23 million0.00News Coverage
Adagene logo
ADAG
Adagene
1.3$19.01+8.8%$827.32 million$700,000.00-7.17Analyst Downgrade
News Coverage
Gap Down
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$31.36+0.4%$825.40 million$9.54 million-6.44
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
1.0$15.80+1.2%$823.34 million$6.48 million-11.29Analyst Report
Gap Up
IVERIC bio logo
ISEE
IVERIC bio
1.6$9.09+2.1%$821.65 millionN/A-7.90Unusual Options Activity
Gap Up
This page was last updated on 7/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.